ActiGraph Releases API Supporting Actigraphy Data Collection
ActiGraph, a leading provider of objective physical activity and sleep/wake monitoring solutions for the global research community, announced today the release of an Application Programming Interface (API) to its popular ActiLife analysis software. The newest addition to ActiGraph’s growing technology suite, the ActiLife API was designed to run within closed systems, ensuring that protocol and regulation compliance requirements are not compromised during data collection.
ActiGraph’s new API allows programmatic control of the ActiLife software over a standard socket, allowing users to develop their own custom applications (Java, C#, C++, etc.) which can automate activity monitor deployments and downloads. An active Internet connection is not required and the ActiLife user interface control can be completely blocked from view, allowing full integration and automation of custom client applications. The ActiLife API currently supports all ActiGraph devices, including the company’s newest wireless wGT3X+ and wActiSleep+ monitors.
“The ActiLife API was primarily developed to support the implementation of ActiGraph’s objective monitoring system within drug trials and clinical research studies,” said Jeremy Wyatt, ActiGraph’s Vice President of Software Engineering. “The tremendous value of objective measures within these markets is finally becoming fully understood, and we are focused on developing tools, like the ActiLife API, that deliver data seamlessly in these complex environments.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
